menu
    • menu
    [{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"CKD Bio Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Healis Therapeutics \/ Healis Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Healis Therapeutics \/ Healis Therapeutics"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Healis Therapeutics \/ Massachusetts General Hospital","highestDevelopmentStatusID":"4","companyTruncated":"Healis Therapeutics \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"||SNAP-25","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Healis Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"CKD Bio Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"CKDB-501","moa":"||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healis Therapeutics \/ Healis Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Healis Therapeutics \/ Healis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Healis Therapeutics

    Menu

    Healis Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serotype A Botulinum Toxin,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Healis Therapeutics Announces Collaboration with MGH and Harvard Medical School

                            Details : The collaboration will focus on Healis’ upcoming clinical trial studying the safety and efficacy of CKDB-501A, a BoNT/A neuromodulator, for the treatment of neuropsychiatric conditions

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            March 26, 2024

                            Lead Product(s) : Serotype A Botulinum Toxin,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Serotype A Botulinum Toxin,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : CKD Bio Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Healis Therapeutics Shares Phase III Topline Results for CKDB-501A Glabellar Injections

                            Details : CKDB-501A (serotype A botulinum toxin) is a novel BoNT/A neuromodulator protein. It is being evaluated for the treatment of moderate-to-severe glabellar lines.

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            February 27, 2024

                            Lead Product(s) : Serotype A Botulinum Toxin,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : CKD Bio Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CKDB-501,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Recipient : CKD Bio Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Healis Announces Supply Agreement With CKD Bio To Develop CKDB-501

                            Details : Under the agreement, Healis intends to develop CKDB-501, a neuromodulator Serotype A botulinum toxin (BoNT/A) protein, for Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            February 01, 2024

                            Lead Product(s) : CKDB-501,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Recipient : CKD Bio Corporation

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Healis Therapeutics

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum Toxin A,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Healis Therapeutics Acquires Ownership of Key Botulinum Toxin Patent

                            Details : After clinically significant results in early trials, Allergan acquired the rights to develop botulinum toxin for depression. Allergan completed a Phase II study in 2017 and announced plans for Phase III. AbbVie assumed ownership through its 2020 acquisi...

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 02, 2022

                            Lead Product(s) : Botulinum Toxin A,Inapplicable

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : AbbVie Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth